Bioasis Technologies Inc. Announces Shareholder Webinar – Yahoo Finance
NEW HAVEN, Conn., Dec. 14, 2022 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI) (OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today is pleased to announce that it will be holding an investor call on Tuesday, December 20th, 2022 at 11:00am EST to discuss the recently announced merger with Midatech Pharma plc. All investors are welcome to attend and can find the web link on the Company’s website at www.bioasis.us.
When: December 20, 2022, 11:00 am EST (US and Canada)
How: Webinar registration
After registering, you will receive a confirmation email containing information about joining the webinar.
Please submit any questions in advance of the webinar to: Graeme Dick
On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D., Executive Chair of the Board
Follow on:
Facebook
Instagram
LinkedIn
Twitter
BTI-E&P
About Bioasis
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The delivery of therapeutics across the blood-brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. For more information about the Company, please visit www.bioasis.us.
Cautionary Statement on Forward-Looking Information
This press release may contain certain forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. In particular, this news release contains forward-looking information pertaining to the following: statements regarding the Arrangement, including with respect to the benefits of the Arrangement and expectations regarding the combined company (including its drug delivery technologies and their progress towards approval and commercialization, its market presence and financial condition); the timing of key Arrangement milestones and closing; the ability of Midatech and Bioasis to satisfy the conditions to and to complete the Arrangement; and expectations regarding the impact of the Arrangement on Midatech and Bioasis including in respect of anticipated financial and operating results, strategy and business, and on stakeholders in general. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of Bioasis to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: the satisfaction of the conditions precedent to the closing of the Arrangement (including the obtaining of all shareholder, court, and regulatory approvals and completion of the Midatech Financing); risks associated with the Arrangement and acquisitions generally; the Arrangement Agreement may be terminated in certain circumstances; Bioasis will incur costs even if the Arrangement is not completed; all necessary approvals and consents may not be obtained; uncertainty regarding the ability of the parties to complete all Arrangement milestones on the intended timing; and other related risks and uncertainties, including, but not limited to, risks and uncertainties relating to Bioasis and its business disclosed in Bioasis’ filings on SEDAR at www.sedar.com. Bioasis undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents Bioasis’ best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Deborah Rathjen, Ph.D., Executive Chair of the Board and CEO
deborah@bioasis.us
203-533-7082
Investor Contact:
Graeme Dick
Colwell Capital Corp.
graeme@colwellcapital.com
403-561-8989
Related Quotes
The legendary investor has just posted a message that might discourage investors from buying stocks.
Investor concerns have yet to abate, with worries given some added impetus this week when Fed Chair Jerome Powell said that the central bank is expecting interest rates to rise to 5.1% by the end of 2023. At that rate, many economists fear that a recession is inevitable. In fact, as a sign that recession might be on the horizon, November retail-sales data showed the biggest drop in over a year. The immediate result was a sudden drop in stocks across the board, but the unintended consequence may
(Bloomberg) — Bulls reeling from the Federal Reserve’s still-hawkish tilt are about to lose a major force that helped tamp down turbulence in US stocks during this week’s macroeconomic drama.Most Read from BloombergTrump Hawks Superhero NFT Trading Cards as Crypto Universe ImplodesIs Putin Finally Getting Smart About His Ukraine Disaster?Elon Musk’s Tesla Share Sales Approach the $40 Billion MarkUS Stocks Drop for a Second Day; Oil Snaps Rally: Markets WrapAn estimated $4 trillion of options is
“Investor frustration is building as the Musk brand has quickly deteriorated over the past six months,” the influential tech analyst wrote. “The Twitter nightmare continues.”
Most investors at least have a few stocks they can brag about. Not so this year with Cathie Wood's ARK Innovation.
Stocks have been on a wild ride this week, and conditions could still get weirder as traders brace for "quadruple witching" on Friday, when a flurry of equity options and futures contracts expire.
Shares of Apple (NASDAQ: AAPL), Amazon (NASDAQ: AMZN), and Microsoft (NASDAQ: MSFT) were all sliding this morning as investors processed the latest Federal Reserve interest rate hike and as investors worry that the Fed could potentially tip the economy into a recession. Making matters worse today, the latest data shows that retail sales are slowing down. As a result, Apple had fallen by 3.4%, Amazon had plunged 4%, and Microsoft had tumbled by 3.1% at 11:31 a.m. ET.
In early trading, shares of Western Digital (NASDAQ: WDC), a manufacturer of computer hard disk drives and solid state drives, plunged more than 10%. Worse, the damage seems to be spreading throughout the computer hardware industry, with shares of semiconductors specialist Intel (NASDAQ: INTC) tumbling 3.3%, and Qualcomm (NASDAQ: QCOM) following everyone else lower — down 3.8%. This morning, Goldman Sachs (NYSE: GS) downgraded Western Digital stock from neutral to sell and cut its price target 28% to just $31 a share.
BERLIN (Reuters) -Volkswagen shareholders gathered in Berlin on Friday to vote at an extraordinary general meeting on the payout of a special dividend of 19.06 euros ($20.28) per share from the proceeds of the listing of Porsche AG. A total of 9.6 billion euros, or 49% of the proceeds of the listing, will be paid out in January if shareholders vote in favour, as is widely expected. In an opening speech, Chief Executive Oliver Blume said the Volkswagen Group was on solid footing, with his first hundred days spent on tasks including reshuffling senior roles, defining the carmaker's strategy for China and North America, and revising its software and platform strategy.
More than 100 years of history shows that the U.S. stock market tends to avoid booking back-to-back annual losses, according to AGF Investments.
Yahoo Finance Live anchor Seana Smith checks out several stocks trending in the after-hours trading session.
(Bloomberg) — Commodities will be the best-performing asset class once again in 2023, handing investors returns of more than 40%, according to Goldman Sachs Group Inc.Most Read from BloombergIs Putin Finally Getting Smart About His Ukraine Disaster?Elon Musk’s Tesla Share Sales Approach the $40 Billion MarkPowell Says Fed Still Has a ‘Ways to Go’ After Half-Point HikeStocks Push Lower as Traders Digest Rate Moves: Markets WrapThe Wall Street bank said that while the first quarter may be “bumpy”
FTSE muted as traders digest weak retail sales figures and take stock after the Bank of England raised interest rates.
Yahoo Finance Live's Julie Hyman discusses the decline in stock for Novavax.
The Nasdaq undercut key support on recession fears, with Apple tumbling. Little is working, but here's the silver lining,
The Oracle of Omaha's $5.9 billion hidden portfolio is home to five amazing companies that are ripe for the picking.
(Bloomberg) — U.S. equity-index futures dropped with European stocks amid concern the resolve of central banks to continue their fight against inflation will tip the economy into a recession.Most Read from BloombergTrump Hawks Superhero NFT Trading Cards as Crypto Universe ImplodesIs Putin Finally Getting Smart About His Ukraine Disaster?Elon Musk’s Tesla Share Sales Approach the $40 Billion MarkUS Stocks Drop for a Second Day; Oil Snaps Rally: Markets WrapContracts on the S&P 500 and Nasdaq 10
The collapse of FTX has sparked a crisis of confidence as crypto tries to rebuild its tarnished reputation. What's ahead for 2023.
Cathie Wood is hoping to catch 2020 in a bottle again. The co-founder, CEO, and lead stock picker of Ark Invest delivered jaw-dropping returns two years ago across her family of funds, but her stock-picking skills have proven mortal in 2021 and 2022. Coinbase (NASDAQ: COIN), Tesla (NASDAQ: TSLA), and Verve Therapeutics (NASDAQ: VERV) are three of the four stocks that Ark Invest was buying yesterday.
In this article, we will discuss the 16 large-cap stocks with insider buying. If you want to explore similar stocks, you can also take a look at 5 Large-Cap Stocks With Insider Buying. Insider buying is a popular way to assess the potential of a company and can be a good indicator to gauge a stock’s performance. When insiders, such […]